Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Unveils Rx Safety Board, Website; Postmarket Surveillance Overhaul Next

Executive Summary

HHS is planning a major overhaul of FDA's postmarketing surveillance system as the centerpiece of its next announcement about upgrades to the drug safety regulatory system

You may also be interested in...



IoM Report Blames FDA Leadership Crisis For Failure To Improve Drug Safety

The Institute of Medicine's report on the current state of FDA's drug safety regulation "may not fully reflect a lot of the changes that have been made" at the Center for Drug Evaluation & Research, Deputy Commissioner for Operations Janet Woodcock said Sept. 22

IoM Report Blames FDA Leadership Crisis For Failure To Improve Drug Safety

The Institute of Medicine's report on the current state of FDA's drug safety regulation "may not fully reflect a lot of the changes that have been made" at the Center for Drug Evaluation & Research, Deputy Commissioner for Operations Janet Woodcock said Sept. 22

One Year After Vioxx, Pendulum May Be Swinging Back To Efficacy At FDA

One year after the withdrawal of Vioxx, FDA appears to be rebalancing its focus from a heightened emphasis on safety towards a greater appreciation of the emerging efficacy of drugs

Related Content

Topics

UsernamePublicRestriction

Register

OM013214

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel